Q-linea AB (publ) (QLINEA) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and thank you everyone for joining during the summer here for Kylenia's second quarter report. You have Stuart Gander, the CEO and President speaking, and I'm joined by our new CFO, Annika Blondo-Henriksen, who will come on later to speak to our financials. The usual disclaimer here, which we'll take as read and understood going forward. And our agenda tracks to our previous quarterly readouts here. I'll spend a little bit of time talking to the commercial update in the market and how we see things unfolding with a focus on the US market. Then we'll speak to the outlook through the year, some of the big things happening and what our operational priorities are before I turn it over to Annika to talk to our financial performance through the quarter and obviously come back around to questions and answers. All right, so for those who only have a few minutes joining us today, the key messages that I would like you to take home are as follows. We did ship out five ASTAR instruments during the quarter. I'll talk to the update there on how that translates into activities on the ground, contracting and test pull-through as we go forward. We did, as many of you will know, get approval from the FDA for our expanded menu, which now is definitively the leader in the market in terms of the panel of drug and bug combinations that it offers to our customers and the reception from the pipeline of customers with whom we've been speaking now for some time has been very positive. For those customers in the US who are live with ASTAR on our version one menu, we've now gone back around and upgraded their software. The last of those have now been completed. We expect that to have an impact on those same customers in terms of pull through as it unlocks more of the menu for their usag...